Bioventus Reports 0.9% Sales Decrease but Achieves Net Income Turnaround in 2025

Bioventus Inc., a global medical device company, reported a net sales decrease of 0.9% to $568.1 million for the year ended December 31, 2025, compared to $573.3 million in 2024. Despite the slight dip in sales, the company achieved a net income of $27.3 million, a significant turnaround from the $47.0 million net loss reported in the previous year. Adjusted EBITDA, a non-GAAP measure used by management to assess operating performance, increased by 6.8% to $116.3 million, compared to $108.9 million in 2024. The company manages its business through two reporting segments, U.S. and International, which accounted for 88% and 12%, respectively, of total net sales during the fiscal year.

The company's financial performance was influenced by several key factors. In the U.S. segment, Pain Treatments and Surgical Solutions experienced sales growth, while Restorative Therapies saw a decline due to the divestiture of the Advanced Rehabilitation Business. Internationally, the divestiture also impacted sales, although growth in Pain Treatments and Surgical Solutions partially offset this effect. The company's gross margin improved slightly to 68.3% from 67.7% in the prior year, driven by a favorable product mix and enhanced collections in the U.S. segment. Selling, general, and administrative expenses decreased by 8.7%, primarily due to lower compensation-related costs and a reduction in shareholder litigation costs.

During 2025, Bioventus strategically focused on strengthening its core markets and investing in emerging technologies. The company initiated full commercial launches of StimTrial and TalisMann, peripheral nerve stimulation (PNS) products, and continued to expand its Ultrasonics platform business. A key development was the entry into an agreement with Apex Biologix to be the exclusive distributor of their XCELL PRP System in the United States, specifically for orthopedic and sports medicine markets. The company also refinanced its debt obligations, entering into a new credit agreement that is expected to provide annual interest expense savings and extend debt maturity.

Looking ahead, Bioventus faces several risks and uncertainties that could impact its future performance. These include risks related to its financial position, such as compliance with covenants under its credit agreement and the need for additional capital. The company is also subject to business-related risks, including dependence on a limited number of products, competition, and the ability to manage growth effectively. Regulatory risks, such as the FDA approval process and healthcare reform, also pose challenges. As of December 31, 2025, the company had approximately 930 employees. The company anticipates that it will cease to be an emerging growth company, and thus be subject to all Section 404 reporting requirements, no later than December 31, 2026.